Cyclin-dependent kinase inhibitors as potential targeted anticancer agents (Q37407079)

20 August 2017

1 reference

title

Cyclin-dependent kinase inhibitors as potential targeted anticancer agents (English)

1 reference

20 August 2017

Ivan Diaz-Padilla

1

1 reference

PubMed ID

19262992

20 August 2017

Lillian L Siu

series ordinal

2

1 reference

PubMed ID

19262992

20 August 2017

Ignacio Duran

series ordinal

3

1 reference

20 August 2017

5 March 2009

1 reference

Investigational New Drugs

20 August 2017

1 reference

20 August 2017

27

1 reference

20 August 2017

586-594

1 reference

20 August 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1007/s10637-009-9236-6

20 August 2017

0 references

cites work

Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-009-9236-6

Flavopiridol, an inhibitor of transcription: implications, problems and solutions

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-009-9236-6

Regulation of RNA polymerase II activity by CTD phosphorylation and cell cycle control

21 January 2018

1 reference

12 December 2020

Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma

1 reference

12 December 2020

Cyclin D-dependent kinases, INK4 inhibitors and cancer

1 reference

12 December 2020

Molecular and pharmacodynamic characteristics of the novel multi-target tumor growth inhibitor ZK 304709.

1 reference

12 December 2020

UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium

1 reference

12 December 2020

Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells.

1 reference

12 December 2020

Cyclin E as a prognostic and predictive marker in breast cancer

1 reference

12 December 2020

Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma.

1 reference

12 December 2020

Cell cycle kinases in cancer

1 reference

12 December 2020

A first-in-man phase I tolerability and pharmacokinetic study of the cyclin-dependent kinase-inhibitor AZD5438 in healthy male volunteers

1 reference

12 December 2020

Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.

1 reference

12 December 2020

In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials

1 reference

12 December 2020

The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial

1 reference

12 December 2020

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

1 reference

12 December 2020

Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points.

1 reference

12 December 2020

UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines

1 reference

12 December 2020

Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms

1 reference

12 December 2020

Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors.

1 reference

12 December 2020

Complexities in the development of cyclin-dependent kinase inhibitor drugs

1 reference

12 December 2020

Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1

1 reference

12 December 2020

Cyclin E ablation in the mouse

1 reference

12 December 2020

Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors

1 reference

12 December 2020

Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.

1 reference

12 December 2020

Cyclin-Dependent Kinases

1 reference

12 December 2020

Proliferation of cancer cells despite CDK2 inhibition.

1 reference

12 December 2020

Phase I study of flavopiridol in combination with Paclitaxel and Carboplatin in patients with non-small-cell lung cancer

1 reference

12 December 2020

A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days

1 reference

12 December 2020

In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00.

1 reference

12 December 2020

A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors

1 reference

12 December 2020

Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer

1 reference

12 December 2020

Phase II study of flavopiridol in patients with advanced colorectal cancer

1 reference

12 December 2020

A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model.

1 reference

12 December 2020

Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma

1 reference

12 December 2020

Targeting the cell cycle: a new approach to cancer therapy

1 reference

12 December 2020

Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol

1 reference

12 December 2020

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

1 reference

12 December 2020

Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma

1 reference

12 December 2020

A phase I pharmacodynamic study of the effects of the cyclin-dependent kinase-inhibitor AZD5438 on cell cycle markers within the buccal mucosa, plucked scalp hairs and peripheral blood mononucleocytes of healthy male volunteers

1 reference

12 December 2020

Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials

1 reference

12 December 2020

Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice.

1 reference

12 December 2020

N-&-N, a new class of cell death-inducing kinase inhibitors derived from the purine roscovitine

1 reference

12 December 2020

Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes.

1 reference

12 December 2020

A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer

1 reference

12 December 2020

The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1

1 reference

12 December 2020

Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia.

1 reference

12 December 2020

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.

1 reference

12 December 2020

A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol

1 reference

12 December 2020

Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53.

1 reference

12 December 2020

The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway

1 reference

12 December 2020

Molecular and Immunohistochemical Analysis of the Prognostic Value of Cell-Cycle Regulators in Urothelial Neoplasms of the Bladder

1 reference

12 December 2020

P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models.

1 reference

12 December 2020

A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer.

1 reference

12 December 2020

10.1007/S10637-009-9236-6

Identifiers

DOI

1 reference

20 August 2017

1 reference

PubMed ID

19262992